Pfizer's share movements are experiencing strong reactions amid spiking coronavirus cases. Various investment firms and hedge funds are reshuffling their stakes, with some like Trust Co. of Vermont, and Arkadios Wealth Advisors, maintaining multi-million dollar holdings in
Pfizer Inc.(NYSE:PFE). Meanwhile, Verity & Verity LLC, and Radnor Capital Management LLC, alongside others, are selling substantial portions of their Pfizer shares. Considered a steadfast dividend stock, many believe Pfizer is undervalued. The company has been proactively selling off substantial shares of Haleon, totalling an astounding $3.05 billion, bolstering the speculation of undervaluation. Rising cases of Covid may imply an increasing demand Pfizer’s products, suggesting potential growth in earnings. The company's 2025 outlook appears in tune with expectations, indicating relative stability in the projected future, prompting the acquisition of new shares by Tallon Kerry Patrick, Pines Wealth Management LLC, and BCS Wealth Management among others. Pfizer's stake sale in Haleon, however, did face mixed responses. JP Morgan suggested a need for more pipeline progress to change narrative, while Smith Anglin Financial LLC lowered its holdings. Still, Pfizer continues to attract both long-term investors and high-profile stakeholders like activist investor Starboard, adding to the optimism of investors for a potential rise in stock value.
Pfizer Stocks News Analytics from Tue, 07 May 2024 07:00:00 GMT to Sat, 18 Jan 2025 22:05:02 GMT -
Rating 6
- Innovation 3
- Information 8
- Rumor -3
